Tier 2 — strong

PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals

Ajla Hodzic Kuerec, Lihuan Guan, Weilan Wang, Duarte Barros, Wejdan M. Alenezi, Jozo Grgic, Vanessa K. Wazny, Jordi Morwani-Mangnani, Mazzarine Dotou, Dingding Zhang, Tong Chen, Jiaqiu Wang, Jane Yu Ying Ong, Jian Hua Tay, Natasha To-Anan, Christian R. Sotelo, Atikah D. Binti Naseer Khan, Wester Bruggink, Sabarinath V. Nair, Saiful A. Bin Mohamed Sukor, Shivaji Rikka, Renee Chng Yee Sin, Hui Min Chong, Faiz Bin Mohamed Hashim, Sharon N. Binte Shahul Hameed, Anees B. Binte Abdul Hamid, Xin Jin, Carmina Fuster, Yong Chen, Anna Milani, Cuilin Zhang, Paul Macary, Timothy R. Singham, Karishma Sachaphibulkij, Michael Dunn, Lin Yi, Andrea B. Maier
GeroScience 2026 Online ahead of print, published July 3, 2026

Bibliography

PubMed
PMID 42393428
DOI
10.1007/s11357-026-02394-6
Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Funded by the XPRIZE Foundation and the National University of Singapore. The paper acknowledges DoNotAge.org for providing SIRT6Activator®, Abinopharm for NMN, Shanghai EGT Synbio Group and Abinopharm for ergothioneine, and Bonerge for urolithin A.
Competing interests
Andrea B. Maier disclosed leadership roles in healthy-longevity organizations and Chi Longevity; Lin Yi disclosed a financial interest in Abinopharm, Inc. as founder and CEO. The other authors declared no competing interests.

Study snapshot

Design8-week single-arm, open-label, non-randomized feasibility and exploratory precision-geromedicine trial protocol
ModelHuman — adults aged 50 to 80 with below-75th-percentile VO2peak and cognitive performance, generally healthy with no more than two stable chronic conditions
Sample20 participants
InterventionMultimodal intervention: sleep and dietary guidance, motivational interviewing/CBT, supervised exercise/exergaming, whey protein, creatine, and SIRT6Activator® (DoNotAge.org) fucoidan 2.4 g/day for all participants; personalized urolithin A, NMN, multivitamin and/or ergothioneine added based on gerotype and response; fucoidan could be increased to 3.6 g/day if immune-function targets were not met
Duration8 weeks
EndpointsFeasibility and adherence; VO2peak; 1RM muscle strength; Thigh muscle thickness and intramuscular fat; NIH Toolbox fluid cognition; CD4/CD8 T-cell ratio; Whole-blood NAD+/NADH; Proteomics and metabolomics; Inflammatory cytokines including IL-6, IL-10, TNF-alpha and IL-1beta; hs-CRP and clinical laboratory panels; Other biological, clinical and digital biomarkers of aging

What the study showed, in plain terms

PROMETHEUS is a peer-reviewed protocol from the NUS Academy for Healthy Longevity testing a precision-geromedicine program in 20 adults aged 50 to 80. Every participant receives a foundational package that includes exercise, diet and sleep guidance, whey protein, creatine and 2.4 g/day of DoNotAge.org SIRT6Activator® (fucoidan). Additional supplements are personalized according to muscle, fitness, cognition and response.

This is important for SIRT6Activator because the branded product is explicitly named in a peer-reviewed human protocol. It is not a standalone SIRT6Activator efficacy trial: many interventions are delivered simultaneously, so any eventual change in healthspan measures cannot be attributed to fucoidan alone.

Key findings

Peer-reviewed protocol for the NUS PROMETHEUS XPRIZE Healthspan semifinal study.

SIRT6Activator® from DoNotAge.org is a foundational intervention at 2.4 g/day for all participants.

If the prespecified immune-function response is inadequate, the protocol allows fucoidan escalation to 3.6 g/day.

Primary outcome domains include muscle, cognition and immune function, matching the XPRIZE Healthspan functional framework.

The paper reports that recruitment finished in December 2025 and the final participant completed the last visit on February 23, 2026; biomarker analyses were underway at publication.

What this study can and cannot tell us

This publication is a protocol; it does not report final efficacy results.

PROMETHEUS is single-arm and open-label, without a placebo control.

SIRT6Activator is given alongside exercise, diet, sleep intervention, whey protein, creatine and personalized supplements, so its independent contribution cannot be isolated.

The ClinicalTrials.gov record still listed the trial as recruiting in March 2026, while the July 2026 paper reports that recruitment and intervention visits had finished; the paper is the more recent source for operational status.

The 20-participant feasibility sample is designed for XPRIZE semifinal development, not definitive efficacy estimation.

Related papers in the corpus

Tier 3
Fucoidans are senotherapeutics that enhance SIRT6-dependent DNA repair
Robbins PD et al. · Research Square (preprint, not peer-reviewed) · 2025
Tier 3
The Identification of a SIRT6 Activator from Brown Algae Fucus distichus
Rahnasto-Rilla MK et al. · Marine Drugs · 2017
Tier 3
SIRT6 activator fucoidan extends healthspan and lifespan in aged wild-type mice
Biashad SA et al. · bioRxiv (preprint) · 2025

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability